First-of-its-kind multi-year collaboration established to co-develop innovative artificial intelligence-based decision support tools for robotic-assisted joint surgery
WARSAW, Ind. and NEW YORK, July 28, 2022 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Hospital for Special Surgery (HSS), the world’s leading academic medical center focused on musculoskeletal health, today announced a first-of-its-kind, three-year agreement to create the HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement. Through the collaboration, ZB and HSS aim to develop new decision support tools, powered by data collection and machine learning, to provide data-driven recommendations to surgeons for robotic-assisted joint surgery.
“Forging a multi-year collaboration with a leading orthopedics institution combines HSS’ clinical expertise with Zimmer Biomet’s expertise in surgical robotics and AI modeling,” said Ivan Tornos, Chief Operating Officer at Zimmer Biomet. “This agreement, which is our second collaboration with HSS in two years, advances our vision to accelerate impactful innovation through strategic third-party relationships.”
The decision support tools, which will be integrated into the ROSA® Knee and ROSA® Hip systems, will further expand the capabilities of ZB’s ZBEdge™ suite of smart, digital and robotic technologies designed to deliver transformative data-powered clinical insights with the goal of improving patient outcomes.
“As a world leader in orthopedics, we strive to find opportunities to innovate towards improving patient care,” said Michael P. Ast, MD, Chief Medical Innovation Officer at HSS. “Leveraging data analytics and AI in this collaboration could enable us to improve clinical results in robotic-assisted joint replacement surgeries.”
Over the course of the collaboration, a team of HSS surgeons and ZB data scientists will work together to develop and test hypotheses that use data-driven insights to address common clinical challenges associated with joint replacement surgery. The goal is to use the validated hypotheses to inform the development of algorithms for the decision support tools.
“Through this unique collaboration, HSS can apply our knowledge and expertise to transform musculoskeletal care with innovative technologies that can improve clinical outcomes, patient experience and cost efficiency in a meaningful way,” said Louis A. Shapiro, President and CEO at HSS.
“Together we hope to create clinically validated decision support tools that rely on real-world patient and procedural data to inform actionable recommendations that help surgeons achieve predictable and reproducible clinical outcomes,” said Nitin Goyal, MD, Chief Science, Technology and Innovation Officer at Zimmer Biomet.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 13th consecutive year), No. 4 in rheumatology by U.S. News & World Report (2021-2022), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2021-2022). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a second consecutive year (2022). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 145 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.
SOURCE Zimmer Biomet Holdings, Inc.